三叶草生物制药有限公司（02197）于2026年2月4日披露截至2026年1月31日的股份变动月报表。公告显示，公司注册股本维持在2,000,000,000股普通股，面值每股USD 0.0001，总额USD 200,000。
报告期内，公司已发行股份（不包括库存股）由上月底的1,297,836,552股增至1,298,037,427股，新增发行200,875股，主要来自期权行使。无库销股增减及股份购回、注销情况。
根据披露的期权计划信息，首次公开发售前购股权计划行使157,500股，首次公开发售后购股权计划行使43,375股，合计行使200,875股。截至本月底，前述期权计划分别余数1,506,817股及32,655,480股可予发行或转让。
公司声明已遵守香港联交所《上市规则》及相关法律。该公告由董事梁朋签署。公司确认截至2026年1月31日相关股本及发行情况符合要求，股本规模保持稳定。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.